Wave Life Sciences

Wave Life Sciences Sees Historic Stock Surge Following Breakthrough in RNA Editing Therapy

6 months ago talkbio0Tagged Clinical Trials, Hereditary Diseases, liver complications, Lung, RNA Editing, surge, Wave Life Sciences, WVE-006

Wave Life Sciences, RNA editing, genetic condition, lung and liver complications, WVE-006, biotech, stock surge, clinical trial data

Takeda Terminates Partnership with Wave Life Sciences on Huntington’s Disease Program

6 months ago talkbio0Tagged Huntington 's disease, News [Publication Type], partnership termination, Takeda, Wave Life Sciences, WVE-003

Takeda, Wave Life Sciences, Huntington’s disease, WVE-003, partnership termination, biotech news

Wave Life Sciences Reports Positive Interim Data for Duchenne Muscular Dystrophy Treatment

7 months ago talkbio0Tagged Clinical Trials, DMD, Does skip, Duchenne, Dystrophin, exon 53, FORWARD-53, Gene Expression, Interim, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Wave Life Sciences, WVE-N531

Wave Life Sciences, Duchenne Muscular Dystrophy, DMD, Exon 53 Skipping, WVE-N531, FORWARD-53 Clinical Trial, Interim Data, Muscle Health, Dystrophin Expression

Wave Life Sciences Achieves Breakthrough in Huntington’s Disease Treatment with WVE-003, Eyes Accelerated Approval

10 months ago talkbio0Tagged Accelerated, allele-selective silencing, Approved, Huntington 's disease, mutant huntingtin protein, Phase Ib/IIa study, RNA medicine, Wave Life Sciences, WVE-003

Wave Life Sciences, Huntington’s disease, WVE-003, Phase Ib/IIa study, accelerated approval, mutant huntingtin protein, allele-selective silencing, RNA medicine